SILVER SPRING, Md.--(BUSINESS WIRE)--Nuvilex, Inc. (OTCQB:NVLX), an emerging biotechnology provider of cell and gene therapy solutions, today discussed the use of the proprietary Cell-in-a-Box® technology, being acquired from SG Austria, as an adjunct to chemotherapy across a spectrum of cancer treatments.
